These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15807174)

  • 1. [Treatment of chronic hepatitis B].
    Dybowska D; Pilarczyk M
    Przegl Epidemiol; 2004; 58 Suppl 1():139-43. PubMed ID: 15807174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B.
    Akarca US; Ersoz G; Gunsar F; Karasu Z; Saritas E; Yuce G; Batur Y
    Antivir Ther; 2004 Jun; 9(3):325-34. PubMed ID: 15259895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
    Lu WL; Xie DY; Yao JL; Yao GB; Cui ZY; Zhang DF; Wu L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    Brooks EA; Lacey LF; Payne SL; Miller DW
    Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
    Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
    Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
    Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
    Jang JW; Choi JY; Bae SH; Yoon SK; Kim CW; Nam SW; Lee CD; Lee YS; Cha SB; Chung KW
    J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
    Sarin SK; Kumar M; Hissar S; Sharma BC
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
    Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
    Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
    Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
    Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
    Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
    Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
    Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The HBeAg/antiHBe seroconversion as a result of lamivudine treatment in children with chronic hepatitis B unresponsive to previous interferon alpha therapy].
    Lebensztejn DM; Skiba E; Sobaniec-Lotowska M; Kaczmarski M
    Pol Merkur Lekarski; 2004 Jun; 16(96):557-9. PubMed ID: 15510896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.